Abhishek Srivastava
No más puestos en curso
Fortuna: 145 $ al 31/03/2024
Perfil
Abhishek Srivastava worked as the Vice President-Cell Therapy Development at Athenex, Inc. He then served as the Vice President-Technical Operations at Alaunos Therapeutics, Inc. Dr. Srivastava holds a doctorate degree from the University of Louisville School of Medicine.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/03/2023 | 80 ( 0.00% ) | 145 $ | 31/03/2024 |
Antiguos cargos conocidos de Abhishek Srivastava.
| Empresas | Cargo | Fin |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2023 |
| ATHENEXPAR | Corporate Officer/Principal | - |
Formación de Abhishek Srivastava.
| University of Louisville School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Abhishek Srivastava
